Linfomas y entidades afines

Difuso de células grandes - Fenotipo B (CD20 positivo)

Rituximab + CHOP

Rituximab + CHOP en linfoma difuso de células grandes (En ancianos) - GELA

- Feugier P, Van Hoof A, Sebban C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 2005; 23:4117–4126.

Impacto del Rituximab en la supervivencia de British Columbia

- Sehn LH, Donaldson J, Chhanabhai M, et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol 2005; 23:5027–5233.

Trasplante autólogo "Upfront"

Trasplante autólogo en primera línea es superior a CHOP en linfomas agresivos - GOELAMS

- Milpied N, Deconinck E, Gaillard F, et al. Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support. N Engl J Med 2004; 350:1287–1295



How I Treat DLBCL

- James O. Armitage How I treat patients with diffuse large B-cell lymphoma. Blood 2007; 110: 29-36

Inspirado en ese artículo, y para clarificar mi mente de algunas confusiones, escribí una sinopsis terapéutica suscinta en mi blog.

Linfoma de Hodgkin

BEACOPP es superior a AVBD en linfomas de Hodgkin de alto riesgo BEACOPP

- Massimo F, Luminari S, Iannitto E, et al. ABVD Compared With BEACOPP Compared With CEC for the Initial Treatment of Patients With Advanced Hodgkin's Lymphoma: Results From the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. J Clin Oncol 2009 27: 805-811

Linfoma Cutáneo de Células T (CTCL) - Sindrome de Sézary (SS)

Revisión de CTCL-SS. Hwang ST, Janik JE, Jaffe ES, Wilson WH. Mycosis fungoides and Sézary syndrome. Lancet. 2008 Mar 15;371(9616):945-57.

Vorinostat en CTCL en recaida/refractario 01. Duvic M, Talpur R, Ni X et al. Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 2007;109:31–39.

Vorinostat en CTCL en recaida/refractario 024. Olsen EA, Kim YH, Kuzel TM et al. Phase IIB multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol 2007;25:3109–3115

Vorinostat: Aprobación de la FDA. Mann BS, Johnson JR, Cohen MH, et al. FDA Approval Summary: Vorinostat for Treatment of Advanced Primary Cutaneous T-Cell Lymphoma. Oncologist 2007 12: 1247-1252